RNS Number : 3319G
Kromek Group PLC
01 June 2026

1 June 2026

Kromek Group plc
("Kromek", the "Company" or the "Group")

PDMR/Director Shareholding, Issue of Equity and Total Voting Rights

Kromek (AIM: KMK), a global detection company delivering best-in-class solutions for the advanced imaging and CBRN detection markets, announces that it has issued and allotted a total of 163,071 ordinary shares of 1p each in the Company ("Ordinary Shares") to satisfy the exercise of options by employees of the Company. This includes the exercise of 150,000 options by Berry Beumer, an Executive Director of the Company, on 28 May 2026. Following this exercise, Mr. Beumer has an interest in 230,000 Ordinary Shares, representing 0.03% of the Company's enlarged issued share capital.

Total voting rights

Application has been made to the London Stock Exchange for the 163,071 Ordinary Shares to be admitted to trading on AIM ("Admission") and it is expected that Admission will become effective at 8 a.m. on or around 4 June 2026. The new Ordinary Shares will rank pari passu with the existing Ordinary Shares in the Company.

Following Admission, the total number of Ordinary Shares in issue will be 655,299,911. This figure may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the share capital of the Company under the Financial Conduct Authority's Disclosure Guidance and Transparency Rules.

Enquiries

Kromek Group plc
Arnab Basu, CEO — +44 (0)1740 626 060
Claire Burgess, CFO

Cavendish Capital Markets Limited (Nominated Adviser and Broker)
Geoff Nash/Giles Balleny/Seamus Fricker - Corporate Finance — +44 (0)20 7220 0500
Andrew Burdis - ECM
Michael Johnson - Sales

Gracechurch Group (Financial PR)
Harry Chathli/Claire Norbury — +44 (0)20 4582 3500

Kromek Group plc

Kromek Group plc is a leading developer of radiation detection and bio-detection technology solutions for the advanced imaging and CBRN detection segments. Headquartered in County Durham, UK, Kromek has manufacturing operations in the UK and US, delivering on the vision of enhancing the quality of life through innovative detection technology solutions.

The advanced imaging segment comprises the medical (including CT and SPECT), security and industrial markets. Kromek provides its OEM customers with detector components, based on its core cadmium zinc telluride (CZT) platform, to enable better detection of diseases such as cancer and Alzheimer's, contamination in industrial manufacture and explosives in aviation settings.

In CBRN detection, the Group provides nuclear radiation detection solutions to the global homeland defence and security market. Kromek's compact, handheld, high-performance radiation detectors, based on advanced scintillation and solid-state readout technology, are primarily used to protect critical infrastructure, events, personnel and urban environments from the threat of 'dirty bombs'.

The Group is also developing bio-security solutions in the CBRN detection segment. These consist of fully automated and autonomous systems to detect a wide range of airborne pathogens.

Kromek is listed on AIM, a market of the London Stock Exchange, under the trading symbol 'KMK'.

Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them

<table>
<tr><td>1</td><td colspan="2">Details of the person discharging managerial responsibilities / person closely associated</td></tr>
<tr><td>a)</td><td>Name</td><td>Berry Beumer</td></tr>
<tr><td>2</td><td colspan="2">Reason for the notification</td></tr>
<tr><td>a)</td><td>Position/status</td><td>Chief Operating Officer and President of the Advanced Imaging Division</td></tr>
<tr><td>b)</td><td>Initial notification /Amendment</td><td>Initial notification</td></tr>
<tr><td>3</td><td colspan="2">Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor</td></tr>
<tr><td>a)</td><td>Name</td><td>Kromek Group plc</td></tr>
<tr><td>b)</td><td>LEI</td><td>213800VLHYXGHEX5VQ48</td></tr>
<tr><td>4</td><td colspan="2">Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted</td></tr>
<tr><td>a)</td><td>Description of the financial instrument, type of instrument

Identification code</td><td>Options over ordinary shares of 1 penny each

GB00BD7V5D43</td></tr>
<tr><td>b)</td><td>Nature of the transaction</td><td>Exercise of options</td></tr>
<tr><td>c)</td><td>Price(s) and volume(s)</td><td><table><tr><td>Price(s)</td><td>Volume(s)</td></tr><tr><td>1p</td><td>150,000</td></tr></table></td></tr>
<tr><td>d)</td><td>Aggregated information
- Aggregated volume
- Price</td><td>N/A</td></tr>
<tr><td>e)</td><td>Date of the transaction</td><td>28 May 2026</td></tr>
<tr><td>f)</td><td>Place of the transaction</td><td>Outside a trading venue</td></tr>
</table>

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

DSHEBLFXQELBBBZ